X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SST-6007 (Sildenafil Citrate) is a topical PDE-5 inhibitor. It is being evaluated in phase 2 clinical trials in women with female sexual arousal disorder.
Lead Product(s): Sildenafil Citrate
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: SST-6007
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Strategic Science & Technologies
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 31, 2024
Details:
Xaciato (clindamycin phosphate) vaginal gel 2% is a USFDA approved medication for the treatment of bacterial vaginosis (BV) in females 12 years of age and older.
Lead Product(s): Clindamycin Phosphate
Therapeutic Area: Infections and Infectious Diseases Product Name: Xaciato
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Organon
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2024
Details:
DARE-LARC1 is an investigational, drug delivery platform designed to store and precisely deliver levonorgestrel therapeutic doses over months or years through a single device.
Lead Product(s): Levonorgestrel
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: DARE-LARC1
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2024
Details:
The net proceeds will support the development of Dare’s late-stage candidates, including SST-6007, a first-in-class topical sildenafil product candidate in development as an over-the-counter treatment for Female Sexual Arousal Disorder.
Lead Product(s): Sildenafil Citrate
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: SST-6007
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $12.0 million Upfront Cash: Undisclosed
Deal Type: Financing December 26, 2023
Details:
DARE-PDM1 (diclofenac) is a vaginal hydrogel which inhibits Cox-1 and Cox-2. It is being evaluated in phase 1 clinical trials for the treatment of primary dysmenorrhea.
Lead Product(s): Diclofenac
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: DARE-PDM1
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2023
Details:
The funding will support the clinical development of Daré’s novel, investigational intravaginal ring (IVR), DARE-PTB1 (progesterone), being developed as a treatment to reduce the risk of preterm birth, for which there are no FDA-approved treatment options.
Lead Product(s): Bio-identical Progesterone
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: DARE-PTB1
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: $2.0 million Upfront Cash: Undisclosed
Deal Type: Funding December 13, 2023
Details:
SST-6007 (sildenafil citrate), a proprietary cream formulation that is specifically designed to locally increase blood flow to the vulvar-vaginal tissue in women, for Female Sexual Arousal Disorder (FSAD).
Lead Product(s): Sildenafil Citrate
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: SST-6007
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 01, 2023
Details:
Under the agreement, Daré has the global rights to Xaciato (clindamycin phosphate vaginal gel), an FDA-approved medication for the treatment of bacterial vaginosis (BV) in females 12 years of age and older.
Lead Product(s): Clindamycin Phosphate
Therapeutic Area: Infections and Infectious Diseases Product Name: Xaciato
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Organon
Deal Size: $192.8 million Upfront Cash: $10.0 million
Deal Type: Licensing Agreement October 16, 2023
Details:
The funding will be used to advance the development of Daré’s investigational contraceptive DARE-LARC1, an investigational, pre-clinical stage contraceptive implant delivering levonorgestrel, through nonclinical proof of principle studies.
Lead Product(s): Levonorgestrel
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: DARE-LARC1
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: NICHD
Deal Size: $49.0 million Upfront Cash: Undisclosed
Deal Type: Funding September 21, 2023
Details:
The net proceeds will be used the commercial launch of XACIATO (clindamycin phosphate) vaginal gel, a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older.
Lead Product(s): Clindamycin Phosphate
Therapeutic Area: Infections and Infectious Diseases Product Name: Xaciato
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Douglas Pharmaceuticals
Deal Size: $7.0 million Upfront Cash: Undisclosed
Deal Type: Financing September 05, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
